A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) - Makker, Vicky; Recio, Fernando O.; Ma, Ling; Matulonis, Ursula A.; Lauchle, Jennifer O.; Parmar, Hema; Gilbert, Houston N.; Ware, Joseph A.; Zhu, Rui; Lu, Shan; Huw, Ling‐Yuh; Wang, Yulei; et al. (Cancer, 2016)
Keywords: apitolisib; endometrial cancer; GDC‐0980; MAGGIE; GDC-0980; endometrial cancer; MAGGIE; apitolisib